Adaptive seamless phase II/III designs - Background, operational aspects, and examples

Drug Information Journal

Volumn 40, Issue 4, 2006, Pages 463-473

  Maca, Jeff ^a,d   Bhattacharya, Suman ^b   Dragalin, Vladimir ^c   Gallo, Paul ^a   Krams, Michael ^c  

^a NOVARTIS   (Switzerland)

^b GENENTECH INC   (United States)

^c Wyeth ^*

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adaptive designs; Seamless designs

Indexed keywords

BAYES THEOREM; CLINICAL RESEARCH; CLINICAL STUDY; CONFIDENCE INTERVAL; PRIORITY JOURNAL; REVIEW; STANDARD; STATISTICAL MODEL; STATISTICAL PARAMETERS;

EID: 33750854113     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/216847900604000412     Document Type: Review

References (28)

1. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J. 2006;40:425-436.
2. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40:437-444.
3. Bechhofer RE, Kiefer J, Sobel M. Sequential Identification and Ranking Problems. Chicago: University of Chicago Press; 1968.
4. Paulson E. A selection procedure for selecting the population with the largest mean from k normal populations. Ann Math Stat. 1964;35:174-180.
5. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989;45:537-547.
6. Schaid DJ, Wieand S, Therneau TM. Optimal two stage screening designs for survival comparisons. Biometrika. 1990;77:659-663.
7. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Stat Med. 2003;22:689-703.
8. Follman DA, Proschan MA, Geller NL. Monitoring pairwise comparisons in multi-armed clinical trials. Biometrics 1994;50:325-336.
9. Hellmich M. Monitoring clinical trials with multiple arms. Biometrics. 2001;57:892-898.
10. Bischoff W, Miller F. Adaptive two-stage test procedures to find the best treatment in clinical trials. Biometrika. 2005;92:197-212.
11. Todd S, Stallard N. A new clinical trial design combining phases II and III: sequential designs with treatment selection and a change of endpoint. Drug Inf J. 2005;39:109-118.
12. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50: 1029-1041.
13. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Stat Med. 1999;18:1833-1848.
14. Brannath W, Posch M, Bauer P. Recursive combination tests. J Am Stat Assoc. 2002;97:236-244.
15. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics. 2001;57:886-819.
16. Liu Q, Pledger GW. Phase II and III combination designs to accelerate drug development. J Am Stat Assoc. 2005;100:493-502.
17. Posch M, Koenig F, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005;24:3697-3714.
18. Bauer P, Einfalt J. Application of adaptive designs-a review. Biometrical J. 2006;48:14.
19. Kelly PJ, Stallard N, Todd S. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. J Biopharm Stat. 2005;15:641-658.
20. Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58:823-831.
21. Berry, DA, Müller P, Grieve AP, et al. Adaptive Bayesian designs for dose-ranging drug trials. In Case Studies in Bayesian Statistics V. Lecture Notes in Statistics. New York: Springer; 2002;162:99-181.
22. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose response studies. Biometrics. 2005;61:738-748.
23. Coburger S, Wassmer G. Sample size reassessment in adaptive clinical trials using a bias corrected estimate. Biometrical J. 2003;45:812-825.
24. Brannath W, König F, Bauer P. Improved repeated confidence bounds in trials with a maximal goal. Biometrical J. 2003;45:311-324.
25. Sampson AR, Sill MW. Drop-the-losers design: normal case. Biometrical J. 2005;47:257-281.
26. Stallard N, Todd S. Point estimates and confidence regions for sequential trials involving selection. J. Statist Plan Inference. 2005;135:402-419.
27. US Food and Drug Administration. Guidance for Clinical Trial Sponsors. Establishment and Operation of Clinical Trial Data Monitoring Committees. Rockville MD: FDA; 2006. Available at: http://www.fda.gov/cber/gdlns/clindatmon. htm. Accessed August 15, 2006.
28. US Food and Drug Administration. Challenge and opportunity on the critical path to new medicinal products. 2006. Available at: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper .html. Accessed August 15, 2006.